Skip to main content
. 2015 Apr 17;10(5):800–807. doi: 10.2215/CJN.10221014

Table 2.

Key baseline laboratory characteristics by occurrence of calcific uremic arteriolopathy adverse event during the study (safety analysis set)

Characteristic CUA (n=25) No CUA (n=3858) P Valuea
Placebo (N1=19) Cinacalcet (N1=6) Total (N1=25) Placebo (N1=1916) Cinacalcet (N1=1942) Total (N1=3858)
Intact PTH (pg/ml) 515 (285, 1339) 857 (344, 2755) 579 (333, 2121) 692 (364, 1693) 694 (363, 1699) 693 (364, 1695) 0.18
Corrected calcium (mg/dl) 9.9 (9.0, 10.6) 10.5 (9.7, 10.8) 10.1 (9.5, 10.6) 9.8 (9.0, 10.7) 9.8 (9.0, 10.7) 9.8 (9.0, 10.7) 0.08
Phosphorus (mg/dl) 6.4 (4.6, 9.5) 6.6 (4.8, 8.2) 6.4 (4.8, 8.8) 6.2 (4.9, 8.4) 6.3 (4.9, 8.3) 6.2 (4.9, 8.4) 0.45
25(OH)D (ng/ml) 14.5 (6, 38) 20.5 (14, 26) 15 (8, 28) 18 (8, 39) 17 (8, 37) 17 (8, 37) 0.44
Alkaline phosphatase (U/L) 91 (59, 151) 129 (59, 500) 91 (59, 166) 108 (65, 232) 107 (64, 248) 108 (65, 24)
Bone alkaline phosphatase (µg/L) 17.53 (9.60, 32.89) 31.51 (10.29, 139.66) 20.96 (10.21, 38.21) 22.92 (11.56, 66.81) 23.09 (11.52, 70.52) 23.02 (11.53, 68.11) 0.12
N-telopeptide (nmol/L) 141.6 (45.6, 280.4) 620.9 (134.4, 1414.1) 196.2 (52.8, 692.8) 249.6 (79.3, 821.0) 261.0 (81.0, 925.4) 255.3 (80.6, 884.9) 0.13
Hemoglobin (g/dl) 11.9 (8.4, 13.2) 11.7 (9.1, 12.7) 11.7 (9.1, 12.7) 11.8 (10.0, 13.8) 11.7 (10.0, 13.5) 11.8 (10.0, 13.6) 0.62
Albumin (g/dl) 3.6 (3.1, 4.0) 3.5 (3.3, 4.2) 3.6 (3.1, 4.0) 3.7 (3.2, 4.1) 3.7 (3.2, 4.1) 3.7 (3.2, 4.1) 0.30
Total protein (g/dl) 7.0 (6.2, 7.7) 6.8 (5.8, 7.1) 6.9 (6.2, 7.5) 7.0 (6.3, 7.7) 6.9 (6.3, 7.7) 6.9 (6.3, 7.7) 0.44
Bicarbonate (mEq/L) 18.8 (14.4, 26.0) 23.3 (18.9, 24.9) 19.3 (14.7, 24.9) 20.4 (15.8, 25.6) 20.3 (15.7, 25.4) 20.3 (15.7, 25.5) 0.63
Creatinine (mg/dl) 9.7 (4.7, 13.6) 10.9 (7.7, 12.8) 10.0 (6.4, 13.2) 9.9 (6.7, 13.9) 9.9 (6.6, 13.9) 9.9 (6.7, 13.9) 0.77

Values are expressed as median (10%, 90% percentile). N1 refers to number of patients in the safety analysis set; n percentages are based on N1. CUA, calcific uremic arteriolopathy; PTH, parathyroid hormone; 25(OH)D, 1,25-dihydroxyvitamin D.

a

Wilcoxon rank-sum test was used for continuous variables and chi-square test was used for categorical variables. Comparisons are between patients who experienced a CUA adverse event compared with those who did not.